Elekta AB stock (SE0000163628): Recent 1.98% gain amid volatility

Elekta AB shares rose 1.98% to kr48.40 on July 23, 2025, on the Stockholm exchange, showing short-term momentum despite a falling trend signal.

Elekta AB (publ), ticker EKTA-B.ST, saw its stock price climb 1.98% on Wednesday, July 23, 2025, closing at kr48.40 after opening from kr47.46. The shares fluctuated 4.76% during the session, reaching a high of kr49.72, according to StockInvest.us as of July 23, 2025. This move followed a buy signal from a pivot bottom on July 22, 2025, offering potential interest for US investors tracking medtech names with global exposure.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta AB (publ)
• Sector/industry: Medical technology (radiation therapy)
• Headquarters/country: Sweden
• Core markets: Americas, Europe, and other regions
• Key revenue drivers: Cancer and brain disorder treatment solutions
• Home exchange/listing venue: Nasdaq Stockholm (EKTA-B)
• Trading currency: SEK

Elekta AB: core business model

Elekta AB develops and provides clinical solutions for treating cancer and brain disorders. The company focuses on radiation therapy systems, software, and services used in oncology and neurosurgery. Its portfolio includes linear accelerators, brachytherapy systems, and positioning tools, serving hospitals worldwide, as described on Simply Wall St as of recent analysis.

With operations spanning the Americas, Europe, and beyond, Elekta emphasizes precision in radiotherapy to improve patient outcomes. The business model relies on equipment sales, service contracts, and software upgrades, generating recurring revenue streams essential for medtech stability.

Main revenue and product drivers for Elekta AB

Key products include the Leksell Gamma Knife for stereotactic radiosurgery and Elekta Harmony for versatile linear accelerators. These drive revenue through sales to cancer centers and upgrades. Brachytherapy afterloader systems also contribute, with the global market valued at USD 1.40 billion in 2025 per market reports.

Service agreements form a significant revenue portion, providing maintenance and support post-installation. Elekta's exposure to growing demand for advanced cancer treatments supports its financials, particularly relevant for US investors as oncology spending rises in the American healthcare system.

Industry trends and competitive position

The radiation oncology market benefits from rising cancer incidence and technological advances in precision therapy. Elekta competes with Varian Medical Systems (now part of Siemens Healthineers) and Accuray, holding a strong position in stereotactic radiosurgery. US market relevance stems from Elekta's installations in major American cancer centers.

Conclusion

Elekta AB's recent 1.98% stock gain on July 23, 2025, highlights short-term momentum amid volatility signals. The company's focus on cancer treatment solutions positions it in a vital medtech segment with US relevance through market exposure. Investors monitor technical levels like support at kr48.34 for future moves.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.